Cardiff Oncology announces ESMO 2022 posters showing onvansertib overcomes irinotecan resistance in RAS-mutated mCRC

Cardiff Oncology, Inc.

Abstract 366P: Onvansertib overcomes irinotecan resistance in RAS-mutated metastatic colorectal cancer in vivo and in patients (EAP).
Abstract 397P: Early ≥90% decrease in KRAS MAF after one cycle predicts higher ORR and longer PFS in ongoing Phase 1b/2 trial.
Additional findings from EAP and trial data to be released during ESMO, subject to embargo policies.
Conference call and webcast on Sept 12, 2022 at 4:30 PM ET to discuss clinical and corporate update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.